Diseases of the cornea are a frequent cause of blindness worldwide. Keratoplasty is an efficient method for treating severely damaged cornea. The functional competence of corneal endothelial cells is crucial for successful grafting, which requires improving the media for the hypothermic cornea preservation, as well as developing the methods for the evaluation of the corneal functional properties. The transport of water and ions by the corneal endothelium is important for the viability and optic properties of the cornea. We studied the impact of SkQ1 on the equilibrium sodium concentration in the endothelial cells after hypothermic preservation of pig cornea at 4°C for 1, 5, and 10 days in standard Eusol-C solution. The intracellular sodium concentration in the endothelial cells was assayed using the fluorescent dye Sodium Green; the images were analyzed with the custom-designed CytoDynamics computer program. The concentrations of sodium in the pig corneal endothelium significantly increased after 10 days of hypothermic preservation, while addition of 1.0 nM SkQ1 to the preservation medium decreased the equilibrium concentration of intracellular sodium (at 37°C). After 10 days of hypothermic preservation, the permeability of the plasma membrane for sodium decreased in the control cells, but not in the cells preserved in the presence of 1 nM SkQ1. Therefore, SkQ1 increased the ability of endothelial cells to restore the intracellular sodium concentration, which makes SkQ1 a promising agent for facilitating retention of the functional competence of endothelial cells during cold preservation.

01 Nov 2018·Pharmaceutical Chemistry Journal

Antioxidant and Antiradical Activity of Drugs Intended for Treating Ophthalmic Disorders

Author: A. I. Matern ; Ya. A. Okulova ; E. R. Gazizullina ; E. L. Gerasimova ; A. V. Ivanova ; V. L. Rusinov

Ten dosage forms intended for ophthalmic use with declared and potential antioxidant properties were investigated.Antioxidant activity was determined using potentiometry with potassium hexacyanoferrate (III) as the oxidant.Antiradical activity was studied using the stable radical 2,2-diphenyl-1-picrylhydrazyl.The reaction half-lives of the investigated dosage forms were determinedRatios of the exptl. antioxidant activity to the content of main active ingredient were assessed.

01 Sep 2017·Anesteziologiia i reanimatologiia

[MITOCHONDRIA-TARGETED ANTIOXIDANTS IN THE PREVENTION OF THE CORNEA EROSION WHEN PERFORMING SURGERY UNDER GENERAL ANESTHESIA.]

Article

Author: Chemodanov, D V ; Gusev, E A ; Grebenchikov, O A ; Sungurov, V A ; Neverovsky, E A ; Likhvantsev, V V

Despite the use of modern methods of prevention, at least 10% of patients operated on for ophthalmic indications not develop corneal erosion as the indirect complication of general anesthesia.OBJECTIVETo reduce the number of ophthalmic complications of general anesthesia by prophylactic use of new mito- chondria-targeted antioxidants - Vizomitin (eye drops).MATERIALS AND METHODS70 patients, which was supposed to perform the average duration of operations under general anesthesia were randomized into 3 groups depending on the method specific (pharmacological) prevention of corneal erosions: (1) control (specic (pharmacological) prevention was not carried out), (2), using preparation "natural tear, and (3) "Vizomitin" preparation. Postoperative biomicroscopy was performed to assess the condition of the cornea, tear film stability was measured and the height of the tear meniscus.RESULTSWhen using eye drops "Vizomitin" value is an indicator of stability of the tear film on the 3rd day after the operation more than in the control group of patients by 51% (p = 0.012) and patients groups, natural tear by 57% (p = 0.013). Surgical interventions performed under general anesthesia, leading to an increase in the number ofpatients with decreased tear meniscus height index of the control group with 4 to 7 patients (p = 0.30) in the group of natural tear from 3 to 11 patients (p = 0.008) . In the group with drug "Vizomitin" the number of such patients is reduced from 7 to 1 (p = 0.018).CONCLUSIONIn the surgical procedures under general anesthesia eye drops "Vizomitin" effectively prevents the devel- opment of corneal erosion.

100 Deals associated with Vizomitin

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Xerophthalmia	Russia	Mitotech SA	31 Dec 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Wet age-related macular degeneration	Phase 3	United States	Mitotech SA	12 Dec 2018
Xerophthalmia	Phase 3	United States	ESSEX BIO-PHARMACY LIMITED	22 Oct 2018
Xerophthalmia	Phase 3	United States	Mitotech SA	22 Oct 2018
Uveitis	Phase 3	Luxembourg	Mitotech SA	29 Jan 2016
Optic Atrophies, Hereditary	Phase 3	Russia	Mitotech SA	26 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Vizomitin

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation